Global Hidradenitis Suppurativa Market, By Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3), Skin Condition (Folliculitis, Pimples, Boils, Deep-Acne, Others), Treatment Type (Surgery, Medications, Photodynamic Therapy (PDT), Laser Treatment, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the hidradenitis suppurativa market is anticipated to grow rapidly during the forecast period. Hidradenitis suppurativa, often known as acne inversa, is a chronic dermatological condition characterized by swollen lumps. Hormonal imbalances, friction from clothing, and sweating cause hidradenitis suppurativa. According to a 2014 article published in Current Dermatology Reports, the condition is also caused by smoking, obesity, and genetic factors. Hence, the demand for hidradenitis suppurativa market is increased.
Data Bridge Market Research analyses that the hidradenitis suppurativa market was valued at USD 696.58 million in 2021 and is expected to reach USD 1,005.88 million by 2029, registering a CAGR of 4.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hidradenitis suppurativa (HS), commonly known as acne inversa, is a chronic inflammatory skin illness that affects the axillae, groin, and under the breasts. It's marked by recurrent or persistent boil-like nodules and abscesses, which lead to a purulent flow, sinusitis, and scarring. HS can have a substantial psychological impact, and many patients experience anxiety, despair, and body image issues as a result.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Million, Volumes in Units, Pricing in USD
Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3), Skin Condition (Folliculitis, Pimples, Boils, Deep-Acne, Others), Treatment Type (Surgery, Medications, Photodynamic Therapy (PDT), Laser Treatment, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Bayer AG (Germany), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Eli Lilly and Company (US), AbbVie Inc. (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.( Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Allergan (Ireland), Merck & Co., Inc. (US), Zydus Cadila (India), Eisai Co., Ltd. (Japan)
Hidradenitis Suppurativa Market Dynamics
- Rise in the prevalence of skin diseases
The increasing prevalence of skin diseases is a major factor driving market expansion (UI). Also, secondary infection, obstruction of hair follicles, and inflammation of particular sweat glands all contribute to the expansion of the hidradenitis suppurativa market.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of hidradenitis suppurativa market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness and increasing number of cases of obesity will expand the hidradenitis suppurativa market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of hidradenitis suppurativa market. Along with this, rising geriatric population and rising incidences of smoking will enhance the growth rate of the market.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hidradenitis suppurativa market growth.
- Technological advancement
In the near future, technologically sophisticated treatments such as laser operations are expected to drive the hidradenitis suppurativa market growth. Furthermore, the hidradenitis suppurativa market is growing due to FDA approvals for medication delivery and clinical trials.
Moreover, rising drug approvals and launches and increase in the number of emerging markets will further provide beneficial opportunities for the hidradenitis suppurativa market growth during the forecast period.
On the other hand, the high cost associated with the treatment will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and delay in procedure of treatment completion maybe due to unawareness of disease to physicians will challenge the hidradenitis suppurativa market. Additionally, the dearth of skilled professionals and side effects involved with the treatment will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This hidradenitis suppurativa market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hidradenitis suppurativa market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
With a 3:1 ratio, women are more likely than men to develop hidradenitis suppurativa. Around 1% of the world's population is affected by the disease. The sickness is not uncommon, although it is uncommon. It can strike at any age, although it is more frequent in those between the ages of 20 and 30.
Hidradenitis suppurativa market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Hidradenitis Suppurativa Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of hidradenitis suppurativa in recent months.
- In March 2022, MoonLake had started the Phase II trial of nanobody, sonelokimab for treating moderate-to-severe hidradenitis suppurativa (HS). Sonelokimab has the potential to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that cause inflammation in the body.
Global Hidradenitis Suppurativa Market Scope
The hidradenitis suppurativa market is segmented on the basis of clinical stage, skin condition, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Hurley Stage 1
- Hurley Stage 2
- Hurley Stage 3
- Hormonal Therapy
- Immunosuppressive Drugs
- Zinc Supplements
- Pain Medication
- Photodynamic Therapy (PDT)
- Laser Treatment
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Hidradenitis Suppurativa Market Regional Analysis/Insights
The Hidradenitis suppurativa market is analysed and market size insights and trends are provided by country, clinical stage, skin condition, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Hidradenitis suppurativa market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the hidradenitis suppurativa market because of the surging adoption of newer techniques in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and rising government initiatives in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Hidradenitis Suppurativa Market Share Analysis
The Hidradenitis suppurativa market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hidradenitis suppurativa market.
Some of the major players operating in the hidradenitis suppurativa market are:
- Zydus Cadila (India)
- Eli Lilly and Company (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Johnson & Johnson Private Limited (US)
- AstraZeneca (UK)
- Merck & Co., Inc. (US)
- Bayer AG (Germany)
- AbbVie Inc. (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Sanofi (France)
- Novartis AG (Switzerland)
- Aurobindo Pharma (India)
- Lupin (India)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Allergan (Ireland)
- Merck & Co., Inc. (US)
- Eisai Co., Ltd. (Japan)